A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
← catalyst calendarNCT05648214 · readout in 355 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
172estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-27 | actual | When the study began enrolling |
| Primary completion | 2027-08-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-10 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
- Drug: ALN-PNP
- Drug: Placebo (PB)
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events (TEAEs)
measured Up to Day 337
Severity of TEAEs
measured Up to Day 337
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed